Wire · opportunities
PILA PHARMA: FIRST SUBJECT FIRST VISIT COMPLETED FOR SAFETY PART 1 OF PP ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
PILA PHARMA has enrolled the first subject for Part 1 (safety) of its PP-CT04 clinical trial investigating the safety, tolerability, pharmacokinetics, and efficacy of XEN-D0501 in obese participants. This randomized, double-blind, placebo-controlled trial aims to explore dose titration of the oral TRPV1 antagonist over 12 weeks in people living with obesity.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup should watch dose escalation strategies for obesity treatments like XEN-D0501, which are now advancing to safety testing. A successful tolerable dosing regimen could open a new pathway for oral obesity drugs in clinical development.
◆ Coverage
1 source · 30 Sep 2026
◆ Related on Wire
◆ Topics